Back to News
Market Impact: 0.35
Genentech's Lunsumio-based Regimen Meets Primary Goal In Phase III Study In Follicular Lymphoma
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Genentech, a Roche affiliate, said its Lunsumio-based regimen significantly improved progression-free survival for follicular lymphoma patients in the Phase III CELESTIMO study. The positive late-stage trial result supports the regimen's clinical profile and could be a favorable catalyst for Roche's oncology portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
- UK Lawmakers Say Thames Creditors Have Been Joyriding Family Car
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Palantir (PLTR) Q4 2025 Earnings: 70% Revenue Growth, Then an 11% Single-Day Crash
- AlphaSense Pricing: What Public Contract Data Shows in 2026